Выбор редакции
12 марта, 16:08

Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

09 марта, 21:18

Pharma Stocks Weighed Down by Competition, Generic Pressure

Pharma Stocks Weighed Down by Competition, Generic Pressure

Выбор редакции
19 января, 18:00

Here's Why Nektar Stock Skyrocketed Almost 500% in a Year

Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.

22 декабря 2017, 16:30

Why is Nektar (NKTR) Stock Up More Than 350% This Year?

Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.

Выбор редакции
22 декабря 2017, 16:28

Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder

Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

24 ноября 2017, 22:39

Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.

21 ноября 2017, 01:43

Azar received millions from Eli Lilly in last year, disclosures show

President Donald Trump's pick for secretary of Health and Human Services collected nearly $2 million in compensation during his final year as president of drug giant Eli Lilly's U.S. operations, new public financial disclosures show.Alex Azar, who left the company in January, also pocketed $1.6 million in severance connected to his departure — and more recently made as much as $1 million from his sale of Eli Lilly stock.Those combined earnings don't include the more than $700,000 that Azar received in assorted payouts at the end of his tenure, ranging from compensation for unused vacation time to an employer match for his savings plan. That represents a substantial slice of Azar's overall financial portfolio, which ranges in value from $9.5 million to more than $20 million, based on estimates in filings with the Office of Government Ethics. And it's likely to ratchet up scrutiny of Azar's ties to the drug industry ahead of confirmation hearings that begin later this month.Multiple Senate Democrats, and independent Vermont Sen. Bernie Sanders, have already declared their opposition to Azar's nomination because of his ties to the drug industry. The Health, Education, Labor and Pensions Committee is set to hold the first confirmation hearing on his nomination Nov. 29.After leaving Indianapolis-based Lilly, Azar leaned heavily on his industry experience to find new work. He collected $46,500 in speaking fees for four events, including ones hosted by the National Association of Specialty Pharmacy and pharma-focused tech company Veeva Systems. Azar also valued his consulting firm's worth at between $15,001 and $50,000. The firm's clientele included the National Pharmaceutical Council and drug company UCB Inc. In an ethics disclosure also filed with the ethics office, Azar pledged to divest interests in a number of health care-related entities, including HMS Holdings, which he served as a board member until he resigned last Friday.Azar also plans to recuse himself for a year from certain issues affecting a series of industry groups, including Eli Lilly, HMS and former consulting clients, unless he first obtains a waiver. Azar said he has already divested his entire $3.4 million stake in Lilly and laid out plans to forfeit or divest all of his HMS equity ownership.He also pledged to refrain until January from participating in matters affecting the Biotechnology Innovation Organization and Healthcare Leadership Council, effectively imposing a one-year cooling off period on himself since his resignation from both health care trade groups.

Выбор редакции
03 октября 2017, 15:53

Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

12 сентября 2017, 17:59

AbbVie's RA Candidate Meets Primary Endpoint in Phase III

AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.

24 июля 2017, 20:19

Послушай клавиш перебор

Пара тесно связанных сюжетов о новостях шпионских технологий – про добычу информации из компьютерных устройств по акустическим сигналам работы клавиатуры. (Май 2004) На проходившем в калифорнийском городе Окленде «Симпозиуме по безопасности и приватности» (9-12 мая 2004) интересный доклад представил наш соотечественник Дмитрий Асонов, работающий ныне в Олмейденском исследовательском центре IBM. Совместная работа Асонова и Ракеша … Читать далее Послушай клавиш перебор →

19 июля 2017, 15:39

Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

17 июля 2017, 17:29

Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).

03 июля 2017, 15:13

Key FDA Events to Watch Out for in Jul 2017

Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?

28 июня 2017, 22:11

Better Days Ahead for the Pharma Sector?

Better Days Ahead for the Pharma Sector?

16 июня 2017, 21:26

Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

09 июня 2017, 15:34

Adamas Provides Positive Long-term Data on Parkinson's Drug

Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.

08 июня 2017, 17:10

AbbVie (ABBV) Announced Positive Phase III RA Candidate Data

AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).

Выбор редакции
25 мая 2017, 16:30

The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

24 мая 2017, 15:37

Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data

Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.